COMMUNIQUÉS West-GlobeNewswire
-
CytoDyn to Showcase PD-L1 Upregulation and Improved Survival in Metastatic Triple Negative Breast Cancer at the San Antonio Breast Cancer Symposium
08/12/2025 -
SS Innovations Submits 510(k) Premarket Notification to the FDA for the Company’s SSi Mantra Surgical Robotic System
08/12/2025 -
IRADIMED Announces Special Cash Dividend of $0.50 Per Share
08/12/2025 -
rYojbaba Subsidiary Sakai Seikotsuin Serves as an Official Trainer at the 2025 Taipei Wake Open
08/12/2025 -
Ernexa Therapeutics Presents New Preclinical Data at American Society of Hematology (ASH) Annual Meeting on Lead Cell Therapy Candidate for Treatment of Ovarian Cancer
08/12/2025 -
Polyrizon Completes FDA Pre-Submission Meeting for PL-14 Allergy Blocker Nasal Spray
08/12/2025 -
Sharecare partners with CLEAR to power trusted digital identity for AskMD, enable secure access to personalized clinical care and benefits
08/12/2025 -
UMC Utrecht Selects PathAI’s AISight® Dx to Accelerate Research on AI Pathology Algorithms
08/12/2025 -
Resmed Receives FDA Clearance for Personalized Therapy Comfort Settings, to be Marketed as Smart Comfort, an AI-Enabled, Digital Medical Device That Helps Personalize CPAP Therapy
08/12/2025 -
Sana Biotechnology Announces Publication in Nature Biotechnology of in vivo Gene Editing of Human Hematopoietic Stem Cells in Preclinical Models Using the Fusogen Platform
08/12/2025 -
SafeSpace Global (SSGC) Announces Strategic Partnership With 911inform to Transform School Safety Across America
08/12/2025 -
Wake Radiology’s Dr. Monica Reddy Recognized as a National Leader on the Radiology Business Forty Under 40 List
08/12/2025 -
March Biosciences Presents Positive Interim Clinical Data from Phase 2 Trial of MB-105 CD5 CAR-T Cell Therapy at ASH 2025 Annual Meeting
08/12/2025 -
Kura Oncology and Kyowa Kirin Report Combination Data for KOMZIFTI™ (Ziftomenib) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory AML
08/12/2025 -
Corvus Pharmaceuticals Presents Final Data from Soquelitinib Phase 1/1b T Cell Lymphoma Trial
08/12/2025 -
Cullinan Therapeutics Showcases Compelling Clinical Data in AML for CLN-049, Novel FLT3xCD3 T Cell Engager, in Oral Presentation at the 67th ASH Meeting
08/12/2025 -
AskForHelpToday.ca Launches in New Brunswick, Improving Access to Mental Health Care
08/12/2025 -
Greenwich LifeSciences Announces Completion of Enrollment in the Open Label Arm of FLAMINGO-01
08/12/2025 -
MediciNova Announces Update and Basic Characteristic Randomized Patients’ of Phase 2/3 Clinical Trial of MN-166 (Ibudilast) in ALS (COMBAT-ALS Clinical Trial) Presented at the 36th International Symposium on ALS/MND
08/12/2025
Pages